EP Patent

EP3310810A1 — Pd-l1 antagonist combination treatments

Assigned to Merck Patent GmbH · Expires 2018-04-25 · 8y expired

What this patent protects

The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

USPTO Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3310810A1
Jurisdiction
EP
Classification
—
Expires
2018-04-25
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.